- Cosmo reports record 2022 financial results exceeding guidance, increased dividend by 10%, confirms 2023 guidance
- Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
- Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Cosmo Pharmaceuticals NV (C43:BRN) closed at 53.77, 4.78% above its 52-week low of 51.32, set on Aug 03, 2022.
51.32Aug 03 202267.84Jan 31 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||965.73m CHF|
|EPS (TTM)||1.87 |
|Annual div (ADY)||0.9741 |
|Annual div yield (ADY)||1.81%|
|Div ex-date||Jun 01 2022|
|Div pay-date||Jun 03 2022|
Data delayed at least 15 minutes, as of Mar 22 2023.